Jazz Pharmaceuticals (JAZZ) Receives a Buy from Cantor Fitzgerald

By Austin Angelo

In a report released today, Brandon Folkes from Cantor Fitzgerald maintained a Buy rating on Jazz Pharmaceuticals (JAZZResearch Report), with a price target of $185. The company’s shares opened today at $136.54.

Folkes commented:

“We have an Overweight rating and a 12-month price target of $185 on JAZZ shares. We believe that the sleep franchise durability remains underappreciated and that the company has an interesting hemo/oncology business that could drive the next leg of growth and evolution for JAZZ. We believe that data readouts in 2019 and upward earnings revisions in both segments of the business will drive upside to JAZZ’s current share price. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $185 price target.”

According to TipRanks.com, Folkes is a 1-star analyst with an average return of -1.0% and a 37.4% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Jazz Pharmaceuticals with a $172.18 average price target, implying a 26.1% upside from current levels. In a report issued on March 19, SunTrust Robinson also initiated coverage with a Buy rating on the stock with a $163 price target.

See today’s analyst top recommended stocks >>

Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $159 million. In comparison, last year the company had a net profit of $232 million.

Based on the recent corporate insider activity of 81 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.